Julian Harrison, an analyst from BTIG, reiterated the Buy rating on Cartesian Therapeutics (RNAC – Research Report). The associated price ...

For this study, outcomes were compared between 2 groups of patients with myasthenia gravis: those who developed exacerbations ...

Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

The FDA has granted Priority Review to nipocalimab for the treatment of antibody positive patients with generalized myasthenia gravis.

Myasthenia gravis (MG) does not have stages but classes. These classes describe the muscles the condition affects and the severity of muscle weakness, which can influence the treatments a doctor ...

USA-based healthcare giant Johnson & Johnson has announced the publication of key Phase III data for nipocalimab in The ...

Phase III Vivacity-MG3 trial shows that nipocalimab, an investigational FcRn blocker, significantly the improves symptoms of generalized myasthenia gravis with a manageable safety profile.

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to ...

H.C. Wainwright reaffirmed a Buy rating on Cartesian Therapeutics shares, maintaining the $45.00 price target, representing a ...

Dubai, United Arab Emirates - There's a lot of brain power that goes into speech. First, there's a thought or idea, which the ...